{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:00:35Z","timestamp":1785477635235,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"\n Background<\/jats:title>\n \n Current eradication therapies for\n Helicobacter pylori (H. pylori<\/jats:italic>\n ) are increasingly compromised by the emergence of antibiotic resistance and adverse side effects. Exploration of non-antibiotic, targeted therapeutic alternatives is essential for effective\n H. pylori<\/jats:italic>\n management.\n <\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To evaluate the therapeutic efficacy of a rationally designed specific antiserum targeting a BabA\n 189\u2212244<\/jats:sub>\n -FrpB4\n 380\u2212395<\/jats:sub>\n fusion peptide against\n H. pylori<\/jats:italic>\n infection.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Using immunoinformatics, the Le\n b<\/jats:sup>\n antigen binding domain of BabA (residues 189\u2013244) and the immunogenic regions of FrpB4 (residues 380\u2013395) were selected and synthesized as a fusion peptide. This engineered peptide was used to immunize rabbits to generate specific polyclonal antiserum. The direct antimicrobial effect was evaluated\n via<\/jats:italic>\n an\n in vitro<\/jats:italic>\n disk diffusion assay, and its impact on\n H. pylori<\/jats:italic>\n adhesion to AGS (human gastric adenocarcinoma cell line) was assessed following bacterial pre-incubation with the antiserum.\n In vivo<\/jats:italic>\n , C57BL\/6J mice were inoculated intragastrically with\n H. pylori<\/jats:italic>\n (1 \u00d7 10\n 9<\/jats:sup>\n CFU). After confirming bacterial colonization in the gastric mucosa, the infected mice (n=6 per group) received a daily oral administration of the antiserum (0.2 mL) for 2 weeks. Therapeutic efficacy was quantified\n via<\/jats:italic>\n gastric bacterial load counting, urease activity measurement, and histological evaluation.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Immunization with the BabA\n 189\u2212244<\/jats:sub>\n -FrpB4\n 380\u2212395<\/jats:sub>\n fusion peptide successfully elicited high-titer specific antibodies.\n In vitro<\/jats:italic>\n , the antiserum significantly restricted\n H. pylori<\/jats:italic>\n growth and reduced bacterial adherence to AGS cells (\n P<\/jats:italic>\n &lt; 0.05).\n In vivo<\/jats:italic>\n , 2 weeks of oral antiserum administration markedly reduced the gastric bacterial burden, suppressed mucosal urease activity (\n P<\/jats:italic>\n &lt; 0.05), and attenuated histological colonization compared with untreated controls.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The specific antiserum targeting the BabA-FrpB4 fusion peptide exhibits significant antimicrobial and anti-adhesive activities against\n H. pylori<\/jats:italic>\n , effectively restricting gastric colonization\n in vivo<\/jats:italic>\n . This immunotherapeutic approach represents a viable non-antibiotic strategy for\n H. pylori<\/jats:italic>\n intervention.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1867770","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:37:33Z","timestamp":1785476253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic suppression of Helicobacter pylori infection in C57BL\/6J mice using specific polyclonal antibodies targeting BabA and FrpB4"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Zhou","sequence":"first","affiliation":[{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapei","family":"Hu","sequence":"additional","affiliation":[{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Xue","sequence":"additional","affiliation":[{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Nie","sequence":"additional","affiliation":[{"name":"Institute of Basic Medicine, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Shi","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Brain Science and Psychiatric-Psychologic Disease, The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dailun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathogenic Biology, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/pharmaceutics17010132","article-title":"Chitosan nanoparticles for enhanced immune response and delivery of multi-epitope Helicobacter pylori vaccines in a BALB\/c mouse model","volume":"17","author":"Amaral","year":"2025","journal-title":"Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e12386","DOI":"10.1111\/hel.12386","article-title":"Survival of Helicobacter pylori in gastric acidic territory","volume":"22","author":"Ansari","year":"2017","journal-title":"Helicobacter"},{"key":"B3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/toxins11110677","article-title":"Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity","volume":"11","author":"Ansari","year":"2019","journal-title":"Toxins"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.gastro.2010.06.047","article-title":"Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia","volume":"140","author":"Arnold","year":"2011","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1371\/journal.ppat.0020110","article-title":"SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans","volume":"2","author":"Aspholm","year":"2006","journal-title":"PLoS Pathog"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0173108","DOI":"10.1371\/journal.pone.0173108","article-title":"Helicobacter pylori infection and low dietary iron alter behavior, induce iron deficiency anemia, and modulate hippocampal gene expression in female C57BL\/6 mice","volume":"12","author":"Burns","year":"2017","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1073\/pnas.0903438106","article-title":"Helicobacter pylori moves through mucus by reducing mucin viscoelasticity","volume":"106","author":"Celli","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12563","DOI":"10.1111\/hel.12563","article-title":"Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases","volume":"24","author":"Chen","year":"2019","journal-title":"Helicobacter"},{"key":"B9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fcimb.2013.00094","article-title":"Common themes and unique proteins for the uptake and trafficking of nickel, a metal essential for the virulence of Helicobacter pylori","volume":"3","author":"De Reuse","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am. J. Surg. Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3748\/wjg.v24.i29.3204","article-title":"Helicobacter pylori and extragastric diseases: a review","volume":"24","author":"Gravina","year":"2018","journal-title":"World J. Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e12843","DOI":"10.1111\/hel.12843","article-title":"Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients","volume":"26","author":"Guo","year":"2021","journal-title":"Helicobacter"},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12967-015-0558-1","article-title":"The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial","volume":"13","author":"Hu","year":"2015","journal-title":"J. Transl. Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley","year":"2011","journal-title":"Nutrients"},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.279.5349.373","article-title":"Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging","volume":"279","author":"Ilver","year":"1998","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-015-0010-7","article-title":"Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans","author":"Jasion","year":"2015","journal-title":"Nutr. J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/1462-2920.13222","article-title":"How Helicobacter pylori senses, targets and interacts with the gastric epithelium","volume":"18","author":"Keilberg","year":"2016","journal-title":"Environ. Microbiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12859-023-05454-2","article-title":"Designing and development of multi-epitope chimeric vaccine against Helicobacter pylori by exploring its entire immunogenic epitopes: an immunoinformatic approach","volume":"24","author":"Keshri","year":"2023","journal-title":"BMC Bioinformat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ampbs.2022.01.001","article-title":"Nickel, an essential virulence determinant of Helicobacter pylori: transport and trafficking pathways and their targeting by bismuth","volume":"80","author":"Kumar","year":"2022","journal-title":"Adv. Microb. Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S0016-5085(97)70155-0","article-title":"standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain","volume":"112","author":"Lee","year":"1997","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1046\/j.1523-5378.2003.00144.x","article-title":"Prevention and suppression of Helicobacter felis infection in mice using colostral preparation with specific antibodies","volume":"8","author":"Marnila","year":"2003","journal-title":"Helicobacter"},{"key":"B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.meegid.2017.02.007","article-title":"A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: an in silico approach","volume":"49","author":"Meza","year":"2017","journal-title":"Infect. Genet. Evol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/00365529109098223","article-title":"Helicobacter pylori urease: properties and role in pathogenesis","volume":"187","author":"Mobley","year":"1991","journal-title":"Scand. J. Gastroenterol. Suppl"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chom.2015.12.004","article-title":"Structural insights into polymorphic ABO glycan binding by Helicobacter pylori","volume":"19","author":"Moonens","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/phar.2318","article-title":"Treatment of Helicobacter pylori in special patient populations","volume":"39","author":"Nguyen","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/biology2031110","article-title":"The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis","volume":"2","author":"Oleastro","year":"2013","journal-title":"Biology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J. Exp. Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3748\/wjg.v27.i7.545","article-title":"Helicobacter pylori: commensal, symbiont or pathogen?","volume":"27","author":"Reshetnyak","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-3083.2008.02138.x","article-title":"Effect of specific colostral antibodies and selected lactobacilli on the adhesion of Helicobacter pylori on AGS cells and the Helicobacter-induced IL-8 production","volume":"68","author":"Rokka","year":"2008","journal-title":"Scand. J. Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1365-2958.2006.05578.x","article-title":"Novel nickel transport mechanism across the bacterial outer membrane energized by the TonB\/ExbB\/ExbD machinery","volume":"63","author":"Schauer","year":"2007","journal-title":"Mol. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/CDLI.9.5.1061-1066.2002","article-title":"Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection","volume":"9","author":"Shin","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1128\/JB.188.4.1245-1250.2006","article-title":"Nickel represses the synthesis of the nickel permease NixA of Helicobacter pylori","volume":"188","author":"Wolfram","year":"2006","journal-title":"J. Bacteriol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s10096-020-03948-y","article-title":"Virulence of Helicobacter pylori outer membrane proteins: an updated review","volume":"39","author":"Xu","year":"2020","journal-title":"Euro. J. Clin. Microbiol. Infect. Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13103","article-title":"Global primary antibiotic resistance rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis","author":"Yu","year":"2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"894206","DOI":"10.3389\/fimmu.2022.894206","article-title":"Oral administration of a Shigella 2aT32-based vaccine expressing UreB-HspA fusion antigen with and without parenteral rUreB-HspA boost confers protection against Helicobacter pylori in mice model","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1867770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:37:34Z","timestamp":1785476254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1867770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":39,"alternative-id":["10.3389\/fmicb.2026.1867770"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1867770","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1867770"}}